Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study-Reference-Cited by-同舟云学术

Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study

Published:2022-08-17 Issue:9 Volume:29 Page:1079-1084
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Kawahara Takashi¹²^ORCID,Miyoshi Yasuhide¹^ORCID,Ninomiya Sahoko¹,Sato Motoki¹,Takeshima Teppei¹^ORCID,Hasumi Hisashi²,Makiyama Kazuhide²^ORCID,Uemura Hiroji¹

Affiliation:

1. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan

2. Department of Urology Yokohama City University, Graduate School of Medicine Yokohama Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15008

Reference17 articles.

1. Efficacy and safety of radium‐223 dichloride in patients with castration‐resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double‐blind, phase 3 ALSYMPCA trial;Hoskin P;Lancet Oncol,2014

2. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study

3. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

4. Ministry of Health LaW.NDB open data.2020. Available from:https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html

5. Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world safety and effectiveness of radium‐223 in patients with metastatic castration‐resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study;International Journal of Cancer;2024-06-26

2. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment;Annals of Nuclear Medicine;2024-03-22

3. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma;Cancers;2023-08-23

4. Bone‐modifying agents are protective for symptomatic skeletal events in Radium‐223 treatment;International Journal of Urology;2023-07-27

5. Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study;World Journal of Urology;2022-12-15